GREAT; GRoningen Early-PD Ambroxol Treatment Trial

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514976-41-00

Acronym

NL77347.042.22

Enrollment

Registered

2024-09-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Brief summary

Comparison of MDS-UPDRS part III motor subscale in the practically defined OFF medication state at 60 weeks

Detailed description

Safety and tolerability by examination of adverse events, F-DOPA PET, MRI, Montreal Cognitive Assessment (MoCA), Non-Motor Symptoms scale (NMSS), Parkinson’s Disease Quality of life questionnaire with 39 items (PDQ-39), GCase activity measuring sphinglolipids in PBMCs and plasma

Interventions

DRUGAMBROXOL

DRUGMicrocrystalline cellulose

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Comparison of MDS-UPDRS part III motor subscale in the practically defined OFF medication state at 60 weeks	—

Secondary

Measure	Time frame
Safety and tolerability by examination of adverse events, F-DOPA PET, MRI, Montreal Cognitive Assessment (MoCA), Non-Motor Symptoms scale (NMSS), Parkinson’s Disease Quality of life questionnaire with 39 items (PDQ-39), GCase activity measuring sphinglolipids in PBMCs and plasma	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026